Advertisement
UK markets close in 2 minutes
  • FTSE 100

    8,077.14
    +36.76 (+0.46%)
     
  • FTSE 250

    19,602.07
    -117.30 (-0.59%)
     
  • AIM

    753.07
    -1.62 (-0.21%)
     
  • GBP/EUR

    1.1658
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2495
    +0.0032 (+0.26%)
     
  • Bitcoin GBP

    50,925.49
    -931.11 (-1.80%)
     
  • CMC Crypto 200

    1,373.10
    -9.48 (-0.69%)
     
  • S&P 500

    5,012.04
    -59.59 (-1.17%)
     
  • DOW

    37,879.29
    -581.63 (-1.51%)
     
  • CRUDE OIL

    82.27
    -0.54 (-0.65%)
     
  • GOLD FUTURES

    2,345.10
    +6.70 (+0.29%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,912.30
    -176.40 (-0.98%)
     
  • CAC 40

    8,021.20
    -70.66 (-0.87%)
     

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, August 6, 2020.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to: https://www.autolus.com/investor-relations/news-and-events/events.

To access the live and subsequent replay of this webcast that will be live for two weeks and view the accompanying slide presentation, please register here.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com